Risk factor
Very poor trading liquidity
Profitability factor
Favourable analyst view
About
Medeon Biodesign, Inc. operates in Taiwan and the United States, specializing in the entire lifecycle of medical devices, from initial research and development to manufacturing and distribution. The company's primary focus is on engineering innovative solutions for minimally invasive surgical procedures. Its diverse product lineup includes Duett, a specific vascular graft system; ClickClean, designed to enhance visibility during laparoscopic operations; AbClose, which helps prevent port site herniation; the UroCross expander system; PUMA, tailored for treating orthopedic extremity injuries; and Cross-Seal, a device for closing large-bore access points. Beyond its own product development, Medeon Biodesign also undertakes contract manufacturing for other medical devices, participates in equity investments and commercial activities within the medical device industry, and produces and sells injection-molded components for medical applications. The company was established in 2012 and maintains its corporate headquarters in Taipei, Taiwan.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.